Clinically-Relevant Weight Loss is Achieved Independently of Early Weight Loss Response to Once-Weekly Subcutaneous Semaglutide 2.4 MG (STEP 4)

Background: Semaglutide, a glucagon-like peptide-1 analogue, is being investigated in people with overweight or obesity. A post-hoc analysis of the STEP 4 trial was conducted to identify whether early weight loss is predictive of later weight loss with maintenance once-weekly subcutaneous (s.c.) sem...

Descripción completa

Detalles Bibliográficos
Autores principales: Mosenzon, Ofri, Garvey, W Timothy, Hesse, Dan, Koroleva, Anna, Kushner, Robert F, Lim, Soo, Lingvay, Ildiko, Wallenstein, Signe O R, Wadden, Thomas A, Le Roux, Carel W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Adipose Tissue, Appetite, and Obesity
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265765/
http://dx.doi.org/10.1210/jendso/bvab048.013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265765/
http://dx.doi.org/10.1210/jendso/bvab048.013

Ejemplares similares